Predicting the Clinical Response to Omalizumab With Anti-Immunoglobulin E (IgE) Ab Response or Syk Expression in Basophils

Part of paid clinical trials in Baltimore, Maryland.

Sponsor
Johns Hopkins University
Study ID
NCT02023151
Phase
PHASE4
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 75 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

This research is being done to test whether differences in blood cells at baseline (start of the study) can be used to predict how well omalizumab will work in a patient. Omalizumab (Xolair) is a drug approved by the U.S. Food and Drug Administration (FDA) to treat asthma. Studies show that omalizumab improves the symptoms of asthma but some people experience better improvement than others.

Key Dates

Start date
Feb 28, 2013
Status verified
Nov 2017
Primary completion
Jun 30, 2016
Completion
Aug 31, 2016

Study Design

Enrollment
17 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Other: Omalizumab
    Active

Primary Outcome Measure

Changes in the Peripheral Blood Basophil Response to Crosslinking Anti-IgE Ab [ Time Frame: baseline and 26 weeks ]

Locations (1)

FacilityCityStateZIPSite coordinators
Johns Hopkins Asthma & Allergy CenterBaltimoreMaryland21212-

Find similar trials in Baltimore, MD

By condition
Asthma
By specialty
PulmonologyLung disease
By research site
Johns Hopkins Asthma & Allergy Center· Baltimore, MD

Related Studies